Marinus Pharmaceuticals Inc (61Y)

Frankfurt
Currency in EUR
0.5100
+0.0050(+1.98%)
Closed

61Y Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-1.7215.3525.4830.99
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa--+793.19%+66.03%+21.63%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa42.2750.517581.42101.32
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-42.27-48.79-59.65-55.94-70.33
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa--15.43%-22.27%+6.22%-25.72%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--2,839.81%-388.75%-219.57%-226.96%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa12.1619.1537.2856.8561.15
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-67.3%+57.53%+94.67%+52.49%+7.58%
aa.aaaa.aaaa.aaaa.aaaa.aa-----
aa.aaaa.aaaa.aaaa.aaaa.aa12.1619.1537.2856.8561.15
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-54.42-67.94-96.93-112.79-131.49
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-46.38%-24.83%-42.68%-16.36%-16.58%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--3,954.42%-631.68%-442.69%-424.3%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa0.350.5-2.5-8.32-8.78
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-22.03%+40.96%-601.4%-232.45%-5.58%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa---2.58-10.67-16.9
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa0.350.50.082.358.11
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.05-0.040.9-1.871.39
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-54.12-67.48-98.53-122.97-138.88
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa---107.38-4
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa---0.24-0.83-0.06
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-54.12-67.48-98.78-16.43-142.94
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-47.36%-24.67%-46.39%+83.37%-770.17%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa--3,927.53%-643.7%-64.48%-461.27%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa---3.39-1.54
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-54.12-67.48-98.78-19.82-141.41
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-54.12-67.48-98.78-19.82-141.41
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-47.36%-24.67%-46.39%+79.94%-613.59%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--3,927.53%-643.7%-77.78%-456.31%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-8.88---
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-54.12-76.36-98.78-19.82-141.41
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-3.97-2.8-2.69-0.51-2.63
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-10.55%+29.49%+3.87%+81.16%-418.77%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-3.97-2.8-2.69-0.51-2.63
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-10.55%+29.49%+3.87%+81.16%-418.77%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa13.6327.2736.739.0753.75
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa13.6327.2736.739.0753.75
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-54.14-67.6-96.58-111.41-126.13
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-46.13%-24.86%-42.86%-15.36%-13.21%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--3,934.98%-629.36%-437.29%-407.01%
EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa